FDA Approves First-Ever PROTAC Drug VEPPANU for Advanced Breast Cancer, a Major Win for Arvinas
ARVN sits 74% above its 52-week low of $5.9 on light trading volume (0.3× avg).
Summary
The FDA has granted accelerated approval for Arvinas's VEPPANU (vepdegestrant) for the treatment of ESR1-mutated, ER+/HER2- advanced breast cancer. This marks a transformative milestone as VEPPANU is the first-ever FDA-approved PROteolysis TArgeting Chimera (PROTAC) therapy, validating Arvinas's pioneering technology. The approval was received ahead of the PDUFA date of June 5, 2026, indicating a strong regulatory outcome. This development is highly significant for Arvinas, representing its first approved medicine and opening a new revenue stream in partnership with Pfizer Inc., which co-developed the drug. The drug addresses a significant unmet medical need for patients who have progressed on prior endocrine therapy. Investors will now focus on the commercialization strategy and the selection of a third party to bring the treatment to market, as well as the implications for Arvinas's broader PROTAC pipeline.
At the time of this announcement, ARVN was trading at $10.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $656.9M. The 52-week trading range was $5.90 to $14.51. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.